Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

  • The following term was not found in PubMed: Thesis1946;.
1.

VEGFC antibody therapy drives differentiation of AML.

Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Mulder AB, Guryev V, Verhagen HJMP, De Keersmaecker K, Smit L, Kornblau SM, De Bont ES.

Cancer Res. 2018 Sep 5. pii: canres.0250.2018. doi: 10.1158/0008-5472.CAN-18-0250. [Epub ahead of print]

PMID:
30185550
2.

Euthanasia and addiction: a comment from the Netherlands.

Boer T.

Addiction. 2018 Jul;113(7):1184-1185. doi: 10.1111/add.14162. Epub 2018 Feb 21. No abstract available.

PMID:
29468767
3.

LEAK study: design of a nationwide randomised controlled trial to find the best way to treat wound leakage after primary hip and knee arthroplasty.

Löwik CAM, Wagenaar FC, van der Weegen W, Poolman RW, Nelissen RGHH, Bulstra SK, Pronk Y, Vermeulen KM, Wouthuyzen-Bakker M, van den Akker-Scheek I, Stevens M, Jutte PC; LEAK study group.

BMJ Open. 2017 Dec 28;7(12):e018673. doi: 10.1136/bmjopen-2017-018673.

4.

Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.

Wijting I, Rokx C, Boucher C, van Kampen J, Pas S, de Vries-Sluijs T, Schurink C, Bax H, Derksen M, Andrinopoulou ER, van der Ende M, van Gorp E, Nouwen J, Verbon A, Bierman W, Rijnders B.

Lancet HIV. 2017 Dec;4(12):e547-e554. doi: 10.1016/S2352-3018(17)30152-2. Epub 2017 Oct 26.

PMID:
29107562
5.

Embracing Complexity beyond Systems Medicine: A New Approach to Chronic Immune Disorders.

Te Velde AA, Bezema T, van Kampen AH, Kraneveld AD, 't Hart BA, van Middendorp H, Hack EC, van Montfrans JM, Belzer C, Jans-Beken L, Pieters RH, Knipping K, Huber M, Boots AM, Garssen J, Radstake TR, Evers AW, Prakken BJ, Joosten I.

Front Immunol. 2016 Dec 12;7:587. doi: 10.3389/fimmu.2016.00587. eCollection 2016.

6.

B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.

Slot LM, Hoogeboom R, Smit LA, Wormhoudt TA, Biemond BJ, Oud ME, Schilder-Tol EJ, Mulder AB, Jongejan A, van Kampen AH, Kluin PM, Guikema JE, Bende RJ, van Noesel CJ.

Am J Pathol. 2016 Dec;186(12):3273-3284. doi: 10.1016/j.ajpath.2016.07.027. Epub 2016 Oct 15.

PMID:
27750045
7.

Primary Polyomavirus Infection, Not Reactivation, as the Cause of Trichodysplasia Spinulosa in Immunocompromised Patients.

van der Meijden E, Horváth B, Nijland M, de Vries K, Rácz EK, Diercks GF, de Weerd AE, Clahsen-van Groningen MC, van der Blij-de Brouwer CS, van der Zon AJ, Kroes ACM, Hedman K, van Kampen JJA, Riezebos-Brilman A, Feltkamp MCW.

J Infect Dis. 2017 Apr 1;215(7):1080-1084. doi: 10.1093/infdis/jiw403.

PMID:
27578847
8.

Turning Points in the Conception and Regulation of Physician-Assisted Dying in the Netherlands.

Koopman JJ, Boer TA.

Am J Med. 2016 Aug;129(8):773-5. doi: 10.1016/j.amjmed.2016.02.025. Epub 2016 Mar 15. No abstract available.

PMID:
26992560
9.

Signaling and molecular basis of bone marrow niche angiogenesis in leukemia.

Shirzad R, Shahrabi S, Ahmadzadeh A, Kampen KR, Shahjahani M, Saki N.

Clin Transl Oncol. 2016 Oct;18(10):957-71. doi: 10.1007/s12094-015-1477-6. Epub 2016 Jan 7. Review.

PMID:
26742939
10.

Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?

van der Sligte NE, Kampen KR, de Bont ES.

Cell Mol Life Sci. 2015 Oct;72(19):3589-98. doi: 10.1007/s00018-015-2019-7. Epub 2015 Aug 31.

11.

Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia.

van der Sligte NE, Kampen KR, ter Elst A, Scherpen FJ, Meeuwsen-de Boer TG, Guryev V, van Leeuwen FN, Kornblau SM, de Bont ES.

Oncotarget. 2015 Jun 20;6(17):14970-81.

12.

Acute myeloid leukemia in the vascular niche.

Cogle CR, Bosse RC, Brewer T, Migdady Y, Shirzad R, Kampen KR, Saki N.

Cancer Lett. 2016 Oct 1;380(2):552-60. doi: 10.1016/j.canlet.2015.05.007. Epub 2015 May 8. Review.

PMID:
25963886
13.

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES.

Mol Cancer Res. 2015 Jun;13(6):982-92. doi: 10.1158/1541-7786.MCR-14-0660-T. Epub 2015 May 5.

14.

Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.

Sie M, den Dunnen WF, Lourens HJ, Meeuwsen-de Boer TG, Scherpen FJ, Zomerman WW, Kampen KR, Hoving EW, de Bont ES.

PLoS One. 2015 Mar 23;10(3):e0122555. doi: 10.1371/journal.pone.0122555. eCollection 2015.

15.

Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.

Kampen KR, Ter Elst A, Mahmud H, Scherpen FJ, Diks SH, Peppelenbosch MP, de Haas V, Guryev V, de Bont ES.

Leukemia. 2014 Mar;28(3):589-99. doi: 10.1038/leu.2013.342. Epub 2013 Nov 18.

PMID:
24240200
16.

Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.

Weidenaar AC, Ter Elst A, Kampen KR, Meeuwsen-de Boer T, Kamps WA, Schuringa JJ, de Bont ES.

Mol Cancer Res. 2013 Apr;11(4):339-48. doi: 10.1158/1541-7786.MCR-12-0113. Epub 2013 Feb 7.

17.

Vascular endothelial growth factor signaling in acute myeloid leukemia.

Kampen KR, Ter Elst A, de Bont ES.

Cell Mol Life Sci. 2013 Apr;70(8):1307-17. doi: 10.1007/s00018-012-1085-3. Epub 2012 Jul 26. Review.

PMID:
22833169
18.

EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion.

Sikkema AH, den Dunnen WF, Hulleman E, van Vuurden DG, Garcia-Manero G, Yang H, Scherpen FJ, Kampen KR, Hoving EW, Kamps WA, Diks SH, Peppelenbosch MP, de Bont ES.

Neuro Oncol. 2012 Sep;14(9):1125-35. doi: 10.1093/neuonc/nos130. Epub 2012 Jun 21.

19.

The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology.

Kampen KR.

Anticancer Drugs. 2012 Apr;23(4):347-54. doi: 10.1097/CAD.0b013e32835004ac. Review.

PMID:
22261741
20.

Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signalling.

Weidenaar AC, ter Elst A, Kampen KR, Meeuwsen-de Boer TG, de Jonge HJ, Scherpen FJ, den Dunnen WF, Kamps WA, de Bont ES.

Br J Cancer. 2011 Dec 6;105(12):1856-63. doi: 10.1038/bjc.2011.460. Epub 2011 Nov 1.

Supplemental Content

Loading ...
Support Center